Abstract: Maleic acid dialkyl esters can be hydrogenated by a catalysed liquid phase hydrogenation with hydrogen to give succinic acid dialkyl esters by carrying out the hydrogenation continuously under a pressure of 50 to 400 bar at a reaction temperature of 30.degree. to 160.degree. C. over oxygen-free and support-free shaped bodies, arranged in a fixed bed, of compressed powders of elements of the iron sub-group of sub-group VIII of the Periodic Table or their alloys or mixtures with one another or their alloys or mixtures with elements of sub-group VI, and in addition hydrogenation-inert elements can be present. The shaped bodies have a compressive strength of 20 to 250 N and an internal surface area of 10 to 80 m.sup.2 /g.

Abstract: The present invention provides for an esterification process comprising a catalyst source of stannous tin and an alkali metal aluminate. In one preferred embodiment the catalyst comprises about 92 parts sand, about 5 parts stannous oxalate, and about 3 parts of a sodium aluminate, by weight, dry basis. This catalyst is particularly useful in making phthalates, adipates, sebacates and azelates which esters are chiefly used plasticizers.

Abstract: There is disclosed a lower range viscosity telomer oil with an acid number of less than 20 and a viscosity range of from 5000 sus to 12,000 sus at 40.degree. C. The lower range viscosity telomer oil product of claim 1 further comprises no more than 4% polyunsaturated fatty acids and a plurality of aliphatic rings, wherein the telomer vegetable oil is made from about 5% to about 15% of a conjugated triglyceride oil, wherein the conjugated triglyceride oil has at least 50% of fatty acids having at least two conjugated double bonds, and from about 85% to about 95% of an unconjugated unsaturated vegetable oil, wherein the unconjugated unsaturated vegetable oil has from about 10% to about 75% of its fatty acids being polyunsaturated and having from about 16 to about 26 carbon atom chain length (unbranched).

Abstract: A carboxylic acid is made by contacting an organic compound having at least one olefinic bond with ozone to form a mixture of ozonization products; contacting the mixture of ozonization products with oxygen to form a mixture of oxidation products; contacting the mixture of oxidation products with oxygen in the presence of an effective amount of a catalyst selected from the group consisting of a manganese-exchanged X-zeolite, a manganese-exchanged Y-zeolite, a manganese-exchanged A-zeolite, or a combination thereof to form said carboxylic acid.

Abstract: Novel acyclic terpene compounds useful as intermediates for producing sarcophytol A which have an anti-carcinogenic promotor activity and anti-tumor activity, which compounds are shown by the following general formula (I): ##STR1## [wherein R.sup.1 is a hydrogen atom, 1-alkoxyalkyl group, tetrahydrofuryl group, tetrahydropyranyl group or acyl group; R.sup.2 is a group of formula: --CHO, --CH.sub.2 OR.sup.3 or ##STR2## (wherein R.sup.3 is a hydrogen atom, 1-alkoxyalkyl group, tetrahydrofuryl group, tetrahydropyranyl group or acyl group; and R.sup.4 is C.sub.1 to C.sub.4 alkyl group) with the proviso that R.sup.1 and R.sup.3 do not represent the same substituents simultaneously; when R.sup.1 is a hydrogen atom, R.sup.3 is not acetyl group or tetrahydropyranyl group; and when R.sup.2 is a group of formula: ##STR3## R.sup.1 is not a hydrogen atom).

Abstract: The invention relates to fatty acid monoglyceride polyglycol ether sulfosuccinates of the general formula ##STR1## where R represents a straight-chain or branched alkyl or alkylene group having from 7 to 21 carbon atoms;R.sup.1 represents H or CO--R;R.sup.2 may represent, independently of each other, H or the group --CO--CH(SO.sub.3.sup.- M.sup.+)--CH.sub.2 --COO.sup.- M.sup.+ ;A represents the same or different and each is an alkylene group having from 2 to 3 carbon atoms;a,b,c,d may be the same or different, from 0 to 5,e being from 1 to 3,f is a multiplication product of c times e, and a+b+f+d is from 2 to 25; andM.sup.+ represents an alkali-metal ion or an ammonium ion, and to their preparation and use.

Abstract: Novel compounds having the structural formula ##STR1## and pharmaceutically acceptable salts and prodrugs thereof, wherein one of R.sup.1 and R.sup.2 is hydrogen and the other is --CH.dbd.CHCOOH, X is >CH--, and Y is --0--; or, alternatively, the bond between X and Y is not present, X is --CH.sub.2 --, and Y is --OH, as well as methods for their use, pharmaceutical compositions containing the same, and a process for their preparation via fermentation.

Abstract: The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.

Abstract: The present invention relates to a partial ester derived from the reaction product of an oxirane containing acid or derivative thereof, and a reactive hydroxyl compound selected from the group consisting of diols, triols, di-diols and 1,4-dihydroxy butane and a halogen containing polymer compositon thereof. The oxirane compound can be derived from the group consisting of epoxidized vegetable oil, epoxidized fish oil, an aliphatic or arylaliphatic containing craboxyl compound having an oxirane group in the aliphatic chain.

Abstract: The invention relates to compounds containing carbonate groups and carbonyl groups and having the general formula ##STR1## in which R stands for a C.sub.1 -C.sub.4 -alkyl radical, an aryl radical, or a radical R.sup.1, whereR.sup.1 has the following formula ##STR2## in which R.sup.2 to R.sup.6 stand for H, alkyl, OH, O-alkyl, SH, S-alkyl, halogen, N(alkyl).sub.2, or N(alkyl)(aryl) and at least one but not more than three of the radicals R.sup.2 to R.sup.6 stand for a radical of the formula ##STR3## in which A, B and C stand for alkylene, cycloalkylene, oxaalkylene, polyoxaalkylene or arylene, k and l both stand for an integer from 1 to 80, and the end group Z stands for alkyl, aryl, alkoxycarbonyl, alkoxycarbonyloxy, or aryl.These compounds are suitable for use as emulsifiers for dispersions.

Abstract: This invention relates to methods for producing optically active hydroxyesters and also to methods for producing and purifying optically active five-membered ring lactones.More specifically, the invention provides methods for efficiently, safely, and selectively producing and purifying optically active (R)-hydroxyester (shown by formula 1) and optically active (S)-hydroxyester (shown by formula 2) in high state of purity at ordinary temperature.The invention also relates to application of the interconvertible optically active (R)-five-membered ring lacton (shown by formula 5).They are intermediates for synthesizing various medicines, agricultural chemicals, and biologically active substances, however especially useful for synthesizing pheromone of a noxious insect, Popillia japonica Newman. ##STR1## (Here, R.sub.1 denotes --C.tbd.C--R.sub.3 or --C.dbd.C--R.sub.3 ; R.sub.2 and R.sub.3 denote straight chain or branched alkyl groups containing 1 to 10 carbon atoms; R.sub.

Abstract: Aryl alkenoic acid derivatives, and physiologically acceptable salts thereof, are provided which are potent leukotriene antagonists and may be used for the treatment of circulatory diseases and preferably for respiratory diseases such as asthma. The derivatives have a general formula I ##STR1## in which X is --S--,W is CH.dbd.CH;o is 1 to 4;n is 2 to 6;m is 0 to 2;T and Z, same or different, represent oxygen or a direct bond;R.sup.2 and R.sup.3, represent hydrogen, or fluorine;A represents carboxyl, CO.sub.2 R.sub.4.sup.4, wherein R.sup.4 is lower alkylR is ##STR2## wherein Y represents carboxyl, CO.sub.2 R.sup.4, wherein R.sup.4 is lower alkylR.sup.7 and R.sup.8, same or different, represent H or lower alkyl;R.sup.9 represents --OH, --O-alkyl, NH.sub.2 or a NHCH.sub.2 CO.sub.2 H group; andR.sup.10 R3 is H.

Abstract: The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.

Abstract: The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and method for inhibiting farnesyl-protein transferase and the farnesylation of the oncogene protein Ras.

Abstract: The invention provides a diester of the formula CH.sub.3 (CH.sub.2).sub.5 CH(OCOR.sup.1)(CH.sub.2).sub.10 COOR.sup.2, in which R.sup.1 is a saturated, branched chain hydrocarbon radical having 15 to 21 carbon atoms and R.sup.2 is a saturated, branched chain hydrocarbon radical having 8 to 22 carbon atoms. Preferably R.sup.1 is a methyl branched chain radical and contains 17 carbon atoms and statistically between 0.5 and 1.0 methyl side-chain per molecule, whereas R.sup.2 contains 18 to 22 carbon atoms with a C.sub.1 -C.sub.8, preferably C.sub.1 side-chain. The invention also provides a wax composition comprising a diester defined above optionally together with a hydrocarbon oil (C.sub.16 -C.sub.32 and saturated), a C.sub.12 -C.sub.22 optionally branched chain fatty acid and a monoester derived from a C.sub.18 to C.sub.22 fatty acid and a C.sub.12 to C.sub.22 alcohol. Furthermore the invention provides cosmetic preparations containing a wax composition as defined above.